iBio, Inc. (NYSE:IBIO) has a beta value of -5.82 and has seen 13,309,520 shares traded in the last trading session. The company, currently valued at $369.76 Million, closed the last trade at $2.12 per share which meant it gained $0.18 on the day or 9.28% during that session. The IBIO stock price is -251.42% off its 52-week high price of $7.45 and 97.64% above the 52-week low of $0.05. If we look at the company’s 10-day average daily trading volume, we find that it stood at 19.5 Million shares traded. The 3-month trading volume is 34.49 Million shares.
The consensus among analysts is that iBio, Inc. (IBIO) is a Buy stock at the moment, with a recommendation rating of 2. None of the analysts rate the stock as a Sell, while none rate it as Overweight. None out of 1 have rated it as a Hold, with 1 advising it as a Buy. None have rated the stock as Underweight. The expected earnings per share for the stock is -$0.05.
iBio, Inc. (NYSE:IBIO) trade information
Sporting 9.28% in the green today, the stock has traded in the green over the last five days, with the highest price hit on Wednesday, Sep 09 when the IBIO stock price touched $2.27-6 or saw a rise of 6.61%. Year-to-date, iBio, Inc. shares have moved 751.41%, while the 5-day performance has seen it change 9.84%. Over the past 30 days, the shares of iBio, Inc. (NYSE:IBIO) have changed -18.46%. Short interest in the company has seen 16.02 Million shares shorted with days to cover at 0.46.
Wall Street analysts have a consensus price target for the stock at $3.1, which means that the shares’ value could jump 46.23% from current levels. The projected low price target is $3.1 while the price target rests at a high of $3.1. In that case, then, we find that the current price level is +46.23% off the targeted high while a plunge would see the stock lose 46.23% from current levels.
iBio, Inc. (IBIO) estimates and forecasts
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -10.1% over the past 5 years. Earnings growth for 2020 is a modest +38.7%.